Immunic Gets Buy Rating from Guggenheim – Dual-Action MS Pill Shows Strong Potential
Guggenheim launches coverage on Immunic at Buy with a $7 target. The dual-action MS drug vidofludimus calcium targets both inflammation and nerve protection – Phase 3 data could drive major gains.